Form SC 13G/A Theravance Biopharma, Filed by: VANGUARD GROUP INC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Leerink Partners Reiterates Market Perform Rating on Theravance Biopharma (TBPH)
November 13, 2024 9:39 AM ESTLeerink Partners analyst David Risinger reiterated a Market Perform rating and $10.00 price target on Theravance Biopharma (NASDAQ: TBPH).
The analyst comments "TBPH reported strong 3Q24 results, including total revenue 12% above consensus and operating income 13% above, but EPS 5% below largely due a non-cash impairment... More
